Journal of Clinical Oncology, Vol 22, No 10 (May 15), 2004: pp. 1926-1933
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.07.193
The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas
Arnab Chakravarti,
Gary Zhai,
Yoshiyuki Suzuki,
Sormeh Sarkesh,
Peter M. Black,
Alona Muzikansky,
Jay S. Loeffler
From the Departments of Radiation Oncology and Biostatistics, Massachusetts General Hospital/Harvard Medical School; Department of Neurosurgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA.
Address reprint requests to Arnab Chakravarti, MD, Massachusetts General Hospital, Department of Radiation Oncology, 100 Blossom St, Founders House, Room 536, Boston, MA 02114; e-mail: achakravarti{at}partners.org
PURPOSE: The objectives of this study were to examine activation patterns of the phosphatidylinositol 3-kinase (PI3K) pathway in gliomas and to examine the prognostic significance of PI3K pathway activation using snap-frozen clinical specimens.
MATERIALS AND METHODS: Levels of expression of PI3K pathway members were assessed in 92 prospectively collected gliomas through quantitative Western analysis using total and phospho-specific antibodies for PI3K, Akt, and p70s6k. Both expression and expression levels of these PI3K pathway members were correlated with histology, markers of apoptosis (cleaved caspase 3), and with clinical outcome (eg, overall survival).
RESULTS: It was determined that activation of all three PI3K pathway members were significantly more frequent in glioblastoma multiforme than in non-glioblastoma multiforme tumors. Levels of phospho-PI3K, phospho-Akt, and phospho-p70s6k were all found to be inversely associated with cleaved caspase 3 levels, suggesting PI3K pathway activation is associated with reduced levels of apoptosis. Perhaps most importantly, activation of PI3K pathway members was found to be significantly associated with reduced survival times when all glioma cases were considered in aggregate. When glioblastoma cases were considered separately, the prognostic value of PI3K activation remained significant, suggesting that PI3K activation may directly be associated with radiation resistance, given that this was the only adjuvant therapy administered to this subset of patients.
CONCLUSION: Activation of the PI3K pathway is significantly associated with increasing tumor grade, decreased levels of apoptosis, and with adverse clinical outcome in human gliomas. Molecular pathways regulating PI3K activation would appear to be promising targets in the clinical management of glioma patients.
Supported by the following grants: NIH KO8CA82163, Massachusetts General Hospital Brian D. Silber Memorial Fund, and Goldhirsh Foundation Award (all to A.C.).
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
D. Opel, M.-A. Westhoff, A. Bender, V. Braun, K.-M. Debatin, and S. Fulda
Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- and Drug-Induced Apoptosis
Cancer Res.,
August 1, 2008;
68(15):
6271 - 6280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Colman and K. Aldape
Molecular Predictors in Glioblastoma: Toward Personalized Therapy
Arch Neurol,
July 1, 2008;
65(7):
877 - 883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. K. Thorarinsdottir, M. Santi, R. McCarter, E. J. Rushing, R. Cornelison, A. Jales, and T. J. MacDonald
Protein Expression of Platelet-Derived Growth Factor Receptor Correlates with Malignant Histology and PTEN with Survival in Childhood Gliomas
Clin. Cancer Res.,
June 1, 2008;
14(11):
3386 - 3394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Brantley and E. N. Benveniste
Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas
Mol. Cancer Res.,
May 1, 2008;
6(5):
675 - 684.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sakurai and N. Osumi
The Neurogenesis-Controlling Factor, Pax6, Inhibits Proliferation and Promotes Maturation in Murine Astrocytes
J. Neurosci.,
April 30, 2008;
28(18):
4604 - 4612.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Chen, L. J. Zhou, M. Entin-Meer, X. Yang, M. Donker, Z. A. Knight, W. Weiss, K. M. Shokat, D. Haas-Kogan, and D. Stokoe
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma
Mol. Cancer Ther.,
April 1, 2008;
7(4):
841 - 850.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Stupp, M. E. Hegi, M. R. Gilbert, and A. Chakravarti
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
J. Clin. Oncol.,
September 10, 2007;
25(26):
4127 - 4136.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. D. Kao, Z. Jiang, A. M. Fernandes, A. K. Gupta, and A. Maity
Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation
J. Biol. Chem.,
July 20, 2007;
282(29):
21206 - 21212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. Pelloski, K. V. Ballman, A. F. Furth, L. Zhang, E. Lin, E. P. Sulman, K. Bhat, J. M. McDonald, W.K. A. Yung, H. Colman, et al.
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
J. Clin. Oncol.,
June 1, 2007;
25(16):
2288 - 2294.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Jiang, N. Pore, G. J. Cerniglia, R. Mick, M.-M. Georgescu, E. J. Bernhard, S. M. Hahn, A. K. Gupta, and A. Maity
Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir
Cancer Res.,
May 1, 2007;
67(9):
4467 - 4473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Opel, C. Poremba, T. Simon, K.-M. Debatin, and S. Fulda
Activation of Akt Predicts Poor Outcome in Neuroblastoma
Cancer Res.,
January 15, 2007;
67(2):
735 - 745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Carducci, L. Musib, M. S. Kies, R. Pili, M. Truong, J. R. Brahmer, P. Cole, R. Sullivan, J. Riddle, J. Schmidt, et al.
Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer
J. Clin. Oncol.,
September 1, 2006;
24(25):
4092 - 4099.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sathornsumetee, A. B. Hjelmeland, S. T. Keir, R. E. McLendon, D. Batt, T. Ramsey, N. Yusuff, B.K. A. Rasheed, M. W. Kieran, A. Laforme, et al.
AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma.
Cancer Res.,
September 1, 2006;
66(17):
8722 - 8730.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. Pelloski, E Lin, L. Zhang, W.K. A. Yung, H. Colman, J.-L. Liu, S. Y. Woo, A. B. Heimberger, D. Suki, M. Prados, et al.
Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma.
Clin. Cancer Res.,
July 1, 2006;
12(13):
3935 - 3941.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Sarkaria, B. L. Carlson, M. A. Schroeder, P. Grogan, P. D. Brown, C. Giannini, K. V. Ballman, G. J. Kitange, A. Guha, A. Pandita, et al.
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Clin. Cancer Res.,
April 1, 2006;
12(7 Pt 1):
2264 - 2271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner
Recent Advances in the Treatment of Malignant Astrocytoma
J. Clin. Oncol.,
March 10, 2006;
24(8):
1253 - 1265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Reardon, J. A. Quinn, J. J. Vredenburgh, S. Gururangan, A. H. Friedman, A. Desjardins, S. Sathornsumetee, J. E. Herndon II, J. M. Dowell, R. E. McLendon, et al.
Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
Clin. Cancer Res.,
February 1, 2006;
12(3):
860 - 868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kaliski, L. Maggiorella, K. A. Cengel, D. Mathe, V. Rouffiac, P. Opolon, N. Lassau, J. Bourhis, and E. Deutsch
Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion
Mol. Cancer Ther.,
November 1, 2005;
4(11):
1717 - 1728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, et al.
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
J. Clin. Oncol.,
August 10, 2005;
23(23):
5294 - 5304.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Rege, C. Y. Fears, and C. L. Gladson
Endogenous inhibitors of angiogenesis in malignant gliomas: Nature's antiangiogenic therapy
Neuro-oncol,
April 1, 2005;
7(2):
106 - 121.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Lefranc, J. Brotchi, and R. Kiss
Possible Future Issues in the Treatment of Glioblastomas: Special Emphasis on Cell Migration and the Resistance of Migrating Glioblastoma Cells to Apoptosis
J. Clin. Oncol.,
April 1, 2005;
23(10):
2411 - 2422.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Blum, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, and Y. Kloog
Ras Inhibition in Glioblastoma Down-regulates Hypoxia-Inducible Factor-1{alpha}, Causing Glycolysis Shutdown and Cell Death
Cancer Res.,
February 1, 2005;
65(3):
999 - 1006.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Shi, S. Bao, J. A. Maxwell, E. D. Reese, H. S. Friedman, D. D. Bigner, X.-F. Wang, and J. N. Rich
Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation
J. Biol. Chem.,
December 10, 2004;
279(50):
52200 - 52209.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|